A Comedy of Capital: Three Ventures

It is a truth universally acknowledged, that an investor in possession of good sense must be in search of profitable ventures. Yet, how often do we find ourselves swayed by the whims of the market, mistaking mere fluctuation for genuine worth? I have observed, over many a season of booms and busts, that a steady hand and a discerning eye are far more valuable than any frantic attempt to ‘time’ the market – a pursuit, I assure you, as futile as trying to catch smoke with a sieve.

Thus, I present to you, not a mere list of stocks, but a small cast of characters upon the stage of commerce. Each possesses a certain…peculiarity, a particular foible that, if understood, may yield a handsome return. Let us examine them, shall we?

Act I: Alphabet – The Scholar Turned Spendthrift

Ah, Alphabet! A company of considerable learning, once content to amass knowledge and display it with elegant restraint. Now, however, it seems seized by a sudden, insatiable hunger for…everything. Mr. Market, that capricious fellow, reacted with a characteristic pout when informed of Alphabet’s ambitious spending plans for 2026. He deemed it a reckless extravagance, a folly worthy of a nobleman squandering his inheritance.

But I, having witnessed many such transformations, perceive a method in this seeming madness. To hoard capital when opportunity beckons is not prudence, but miserliness. Alphabet, like any sensible scholar, understands that true progress demands investment – in artificial intelligence, in quantum computing, in all the promising, yet unproven, sciences that may shape our future. To balk at such expenditure would be a dereliction of duty, a betrayal of its intellectual calling.

Therefore, I submit that Alphabet is not a spendthrift, but a visionary. And a visionary, my friends, is always a sound investment.

Act II: Amazon – The Merchant Prince and His Endless Emporium

Amazon, that tireless merchant prince, continues to expand his empire with an energy that is both admirable and slightly unsettling. He missed, by a hair’s breadth, the recent earnings estimates, a minor setback that sent the more sensitive investors into a flutter. But to judge Amazon by a single quarter’s results is akin to judging a king by the state of his breakfast.

The true measure of Amazon lies in its relentless pursuit of efficiency and innovation. The $200 billion earmarked for capital expenditure is not a cause for alarm, but a testament to its ambition. The bulk of this sum will be directed towards Amazon Web Services, a realm where demand outstrips supply, and where every investment yields a bountiful return. As the CEO, Mr. Jassy, aptly observed, they are monetizing capacity as quickly as it can be installed. A truly remarkable feat, and one that should inspire confidence, not consternation.

To sell Amazon shares on such a pullback is to misunderstand the very nature of commerce. It is to believe that a merchant should cease to expand, a king to relinquish his domain. I, for one, have no such illusions. I believe Amazon will continue to prosper, and those who invest wisely will share in its success.

Act III: BeOne Medicines – The Alchemist’s Promise

Now we turn to a more delicate matter: the realm of medicine, where hope and despair dance a perpetual waltz. BeOne Medicines, a company brimming with promise, has soared in recent months, fueled by a series of encouraging developments. But let us not be swept away by enthusiasm. A rising tide lifts all boats, but it does not guarantee a safe passage.

The success of Brukinsa, its blood cancer therapy, is indeed noteworthy. The anticipated results from the Phase 3 study and the potential approval of sonrotoclax are cause for optimism. And the prospect of further regulatory filings adds another layer of excitement. But these are merely potential catalysts, not guarantees of success.

What truly distinguishes BeOne is its relentless pursuit of innovation. It is a company that continually strives to push the boundaries of medical science, to develop new and more effective treatments for devastating diseases. And that, my friends, is a reason to buy and hold this stock for the long term. For in the end, it is not merely profit that drives us, but the hope of alleviating suffering and improving the human condition.

Thus concludes our little drama. May your investments be prosperous, and your portfolios filled with the fruits of wisdom and discernment.

2026-02-21 11:52

Act I: Alphabet – The Scholar Turned Spendthrift

Act II: Amazon – The Merchant Prince and His Endless Emporium

Act III: BeOne Medicines – The Alchemist’s Promise

Read More